Cynthia X Ma
Washington University School of Medicine · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Cynthia X Ma as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:01 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06374459 · Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisWashington University School of Medicine · recruiting · Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer · principal investigator
- Ph1NCT05791474 · ATI-2231 in Advanced Solid Tumor MalignanciesWashington University School of Medicine · withdrawn · Advanced Solid Tumor, Advanced Solid Tumor Malignancies · principal investigator
- Ph1NCT03939897 · Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerNational Cancer Institute (NCI) · active not recruiting · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma · principal investigator
- Ph2NCT03007979 · Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast CancerWashington University School of Medicine · completed · Breast Cancer, Breast Carcinoma, Cancer of Breast · principal investigator
- Ph2NCT01723774 · PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerWashington University School of Medicine · active not recruiting · Breast Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 54 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Regulation of resistance to CDK4/6 inhibitor in breast cancerR01CA275904 · NCI · GEORGE WASHINGTON UNIVERSITY · fiscal years 2023 to 2026 · $633,959 awarded in 2026Same name and institution; not confirmed by an ID
- Research Project 1U54CA224083 · NCI · WASHINGTON UNIVERSITY · fiscal years 2017 to 2026 · $209,925 awarded in 2026Same name and institution; not confirmed by an ID
- Washington University Co-Clinical Imaging Research ResourceU24CA209837 · NCI · WASHINGTON UNIVERSITY · fiscal years 2022 to 2026 · $645,323 awarded in 2026Same name and institution; not confirmed by an ID
- FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancerR01CA273194 · NCI · WASHINGTON UNIVERSITY · fiscal years 2022 to 2025 · $1,254,028 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT03939897
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2014 to 2019Named on NCT03939897
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:01 UTC. The ranking covers the 200 most relevant of 33 PubMed records, and a shared surname and initials can bring in a namesake. All 33 on PubMed
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol · 2012419 citationsRCR 10.3
- NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.Clin Cancer Res · 2017311 citationsRCR 8.9
- 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.Clin Cancer Res · 2017306 citationsRCR 11.4
- 275 citationsRCR 7.9
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.Clin Cancer Res · 2017167 citationsRCR 4.6
- Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome.Gastroenterology · 2018143 citationsRCR 7.1
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Breast Cancer Res Treat · 201390 citationsRCR 2.3
- 83 citationsRCR 2.3
- Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.Genome Med · 202479 citationsRCR 9.0
- 77 citationsRCR 38.5